Apyx Medical Corporation Reports Record Q4 2025 Revenue and Significant Reduction in Net Loss; Issues Positive 2026 Guidance

Apyx Medical Corporation (Nasdaq: APYX) has announced its financial results for the fourth quarter and year ended December 31, 2025. The report highlighted record revenue growth, a marked improvement in profitability metrics, and a positive outlook for the year ahead, all of which are key indicators for investors and could be price sensitive.

Key Financial Highlights for Q4 and Full Year 2025

• Record Q4 Revenue: The company posted a record total revenue of \$19.2 million in the fourth quarter of 2025, representing a significant increase from \$14.2 million in the prior-year period. This robust growth underscores strong product demand and execution.
• Net Loss Shrinks: Net loss attributable to stockholders improved significantly, coming in at \$1.3 million for Q4 2025, compared to a net loss of \$4.6 million in Q4 2024. For the full year 2025, net loss attributable to stockholders was \$11.2 million (or \$0.27 per share), compared to \$23.5 million (or \$0.66 per share) in 2024—an improvement of over 50%.
• Adjusted EBITDA Loss Narrows: Adjusted EBITDA loss for the year ended December 31, 2025, was \$3.8 million, a substantial improvement from \$14.3 million the prior year, reflecting better operational efficiency and cost management.
• Gross Profit: Gross profit for Q4 2025 was \$12.0 million, up from \$9.0 million in the same period of 2024.

Balance Sheet and Liquidity

• Total Assets: As of December 31, 2025, total assets stood at \$66.8 million.
• Cash and Equivalents: Cash and equivalents were reported at \$7.6 million.
• Long-term Debt: The company had long-term debt (net of discounts and issuance costs) of \$34.8 million.
• Total Stockholders’ Equity: Closing the year at \$14.5 million.

2026 Financial Guidance – Price Sensitive Information

Apyx Medical has issued optimistic guidance for the full year ending December 31, 2026:

• Revenue: Expected to be in the range of \$57.5 million to \$58.5 million, representing growth from \$52.8 million in 2025.
• Operating Expenses: Operating expenses are anticipated to be less than \$45.0 million for 2026, suggesting ongoing cost discipline and operating leverage.

This guidance reflects management’s confidence in continued momentum and may be viewed as price sensitive information by the market.

Other Notable Items

• Flat Income Tax Expense: Income tax expense remained steady at \$0.3 million for both 2025 and 2024.
• Other Expenses: Other expense, net was \$4.4 million in 2025 versus \$4.5 million in 2024.
• Weighted Average Shares: 42.2 million in 2025 compared to 38.2 million in 2024, indicating potential dilution or capital raising activities during the year.
• No Preferred Stock Issued: The company continues to have no preferred stock outstanding.

Shareholder Considerations & Price Sensitivity

• Significant top-line growth signals market share gains and/or robust product adoption, both positive for valuation.
• Marked reduction in losses and improved adjusted EBITDA suggest the company is on a path to profitability, which can be a major share price catalyst.
• 2026 guidance for continued revenue growth and expense control is likely to be well received by investors and analysts, especially after a year of operational improvement.
• Balance sheet health remains a focus for investors, especially with ongoing debt and modest cash levels. The company’s ability to fund growth without further dilution or increased debt will be important to monitor.

Forward-Looking Statements

Management noted that forward-looking statements—including projections of revenue, margins, expenses, and regulatory events—are subject to risks and uncertainties, including but not limited to macroeconomic factors, supply chain disruptions, regulatory approvals, litigation, and other factors detailed in the company’s SEC filings.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. Investors should review the company’s full filings and consult with a qualified financial advisor before making investment decisions.

View Apyx Medical Corp Historical chart here